Vibativ Side Effects
Generic Name: telavancin
Note: This document contains side effect information about telavancin. Some of the dosage forms listed on this page may not apply to the brand name Vibativ.
Some side effects of Vibativ may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to telavancin: intravenous powder for solution
Along with its needed effects, telavancin (the active ingredient contained in Vibativ) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking telavancin:Less common
- Blood in the urine
- change in the frequency of urination or amount of urine
- difficulty with breathing
- increased thirst
- loss of appetite
- nausea or vomiting
- swelling of the feet or lower legs
- Abdominal or stomach tenderness
- chills or fever
- difficulty with swallowing
- dizziness, faintness, or lightheadedness, especially when getting up suddenly from a lying or sitting position
- fast heartbeat
- itching of the skin
- nausea or vomiting
- pain, redness, or soreness at the site of injection
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- rash or redness of the face, base of the neck, upper body, back, and arms
- severe abdominal or stomach cramps and pain
- tightness in the chest
- unusual tiredness or weakness
- watery and severe diarrhea, which may also be bloody
Some side effects of telavancin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Bad, unusual or unpleasant (after) taste
- change in taste
- foamy urine
- Decreased appetite
- dry, red, hot, or irritated skin
- feeling unusually cold
For Healthcare Professionals
Applies to telavancin: intravenous powder for injection
Complicated skin and skin structure infections: Serious side effects were reported in 7% of telavancin-treated patients during clinical trials and most often included renal, respiratory, or cardiac events. Telavancin (the active ingredient contained in Vibativ) was discontinued due to side effects (generally nausea and rash [about 1% each]) in 8% of patients. The most common side effects reported included taste disturbance, nausea, vomiting, and foamy urine in at least 10% of patients.
Hospital-acquired and ventilator-associated bacterial pneumonia: Telavancin-treated patients with preexisting moderate/severe renal dysfunction (CrCl 50 mL/min or less) had increased mortality versus those treated with vancomycin. Serious side effects were reported in 31% of telavancin-treated patients during clinical trials. Telavancin was discontinued due to side effects (generally acute renal failure and prolonged electrocardiogram QTc interval [about 1% each]) in 8% of patients. The most common side effect was diarrhea (at least 10%).
Very common (10% or more): Taste disturbance (described as a metallic or soapy taste; 33%)
Frequency not reported: Dizziness, headache
Very common (10% or more): Nausea (up to 27%), vomiting (up to 14%)
Common (1% to 10%): Diarrhea (7%)
Frequency not reported: Clostridium difficile-associated diarrhea, abdominal pain
Very common (10% or more): Increased serum creatinine to 1.5 times baseline (up to 16%), foamy urine (13%), renal events indicative of renal impairment (increased serum creatinine, renal impairment, renal insufficiency, and/or renal failure; up to 10%)
Common (1% to 10%): Acute renal failure (5%)
Frequency not reported: Nephrotoxicity
Common (1% to 10%): Rigors (4%)
Frequency not reported: Infusion-related reactions, infusion site pain, infusion site erythema
Common (1% to 10%): Decreased appetite (3%)
Postmarketing reports: Serious hypersensitivity reactions (including anaphylactic reactions)
Serious hypersensitivity reactions (including anaphylactic reactions) reported after first or subsequent doses of telavancin.
Frequency not reported: QTc interval prolongation
Frequency not reported: Pruritus, rash
More about Vibativ (telavancin)
Compare with other treatments for:
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.